Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: A case series

Journal of the Canadian Dental Association

Volumn 74, Issue 6, 2008, Pages 537-542

  Schwartz, Stephane ^a,b   Joseph, Clara ^c   Iera, Deborah ^b   Vu, Duy Dat ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c Paris 5 Descartes University EA 2496 U F R of Odontology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADOLESCENT; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CHILD; DECIDUOUS TOOTH; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; JAW DISEASE; MALE; OSTEOGENESIS IMPERFECTA; PRESCHOOL CHILD; REVIEW; RISK FACTOR; TOOTH EXTRACTION; WOUND HEALING;

ADOLESCENT; BONE DENSITY CONSERVATION AGENTS; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAW DISEASES; MALE; OSTEOGENESIS IMPERFECTA; OSTEONECROSIS; RISK FACTORS; TOOTH EXTRACTION; TOOTH, DECIDUOUS; WOUND HEALING;

EID: 48849115474     PISSN: 07098936     EISSN: 14882159     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005; 39(4):668-77. Epub 2005 Mar 8.
2. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Sur Am 2005; 87(7):1609-18.
3. Marx RE, Sawati Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63(11):1567-75.
4. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104(1): 83-93.
5. Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, and others. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005; 11(6):365-9.
6. Shaw NJ, Bishop NJ. Bisphosphonate treatment of bone disease. Arch Dis Child 2005; 90(5):494-9.
7. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws (approved by the Board of Trustees September 25, 2006). Available: www.aaoms.org/docs/position_papers/ osteonecrosis.pdf (accessed 2008 June 2).
8. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005; 136(12):1658-68.
9. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006; 137(8):1144-50.
10. Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, and other. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25(6):786-91.
11. Rauch F, Glorieux FH. Treatment of children with osteogenesis imperfecta. Curr Osteoporos Rep 2006; 4(4):159-64.
12. Syndromes affecting bone: the osteogenesis imperfecta. In: Gorlin RJ, Cohen MM Jr, Hennekam RC. Syndromes of the head and neck. 4th ed. Oxford: Oxford University Press; 2001. p. 178-91.
13. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339(14):947-52.
14. Plotkin H, Rauch F, Bishop N, Montpetit K, Rick-Gibis J, Travers R, and other. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85(5):1846-50.
15. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects on long-term therapy. J Clin Endocrinol Metab 2006; 91(2):511-6. Epub 2005 Nov 15.
16. Rauch F, Glorieux FH. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Ann Med 2005; 37(4):295-302.
17. Forest D. Bisphosphonates and osteonecrosis of the jaw: update. Journal de l'Ordre des dentistes du Québec Sep 2006; 43:319.
18. Khan M, Khan A. The truth about osteonecrosis of the jaw. Can J Diagn Aug 2006; 81-2.
19. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144(10):753-61.
20. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg 2005; 33(6):395-403. Epub 2005 Oct 25.
21. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 91(2):511-6. Epub 2005 Nov 15.
22. Chahine C, Cheung MS, Head T, Schwartz S, Glorieux F, Rauch F. Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr. In press 2008.
23. Lam DK, Sándor GKB, Holmes HI, Evans AW, Clokie CM. Bisphosphonate-associated osteonecrosis of the jaws: a review for dentists. J Can Dent Assoc 2007; 73(5):171-6.